$26.75
3.88% today
Nasdaq, Feb 05, 04:21 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Stock price

$25.75
-0.61 2.31% 1M
+0.14 0.55% 6M
+0.95 3.83% YTD
-0.18 0.69% 1Y
-35.58 58.01% 3Y
+7.00 37.33% 5Y
+7.00 37.33% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.16 0.63%
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Key metrics

Market capitalization $2.13b
Enterprise Value $1.37b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.91
P/S ratio (TTM) P/S ratio 6.10
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth 328.73%
Revenue (TTM) Revenue $349.64m
EBIT (operating result TTM) EBIT $-182.67m
Free Cash Flow (TTM) Free Cash Flow $-145.37m
Cash position $925.76m
EPS (TTM) EPS $-1.76
P/E forward negative
P/S forward 41.08
EV/Sales forward 26.37
Short interest 17.04%
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Beam Therapeutics Inc forecast:

11x Buy
65%
6x Hold
35%

Analyst Opinions

17 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
65%
Hold
35%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
350 350
329% 329%
100%
- Direct Costs 22 22
22% 22%
6%
328 328
512% 512%
94%
- Selling and Administrative Expenses 82 82
104% 104%
24%
- Research and Development Expense 406 406
6% 6%
116%
-161 -161
57% 57%
-46%
- Depreciation and Amortization 22 22
22% 22%
6%
EBIT (Operating Income) EBIT -183 -183
54% 54%
-52%
Net Profit -144 -144
54% 54%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York.
Neutral
GlobeNewsWire
13 days ago
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of...
Neutral
GlobeNewsWire
23 days ago
More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 436
Founded 2017
Website www.beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today